Adveq

Cedilla is a developer of therapeutics technologies intended to broaden the reach of small molecule therapeutics. The company's technology is focused on destabilizing oncoprotein targets that are also applicable to therapies outside of oncology, enabling doctors to treat diseases caused by protein dysregulation. The company was founded in 2018 and based in Cambridge, Massachusetts.

Alentis Therapeutics AG develops and manufactures medications to treat advanced liver diseases. It develops medications for liver fibrosis, cirrhosis, and liver cancer. The company was founded in 2019 and is based in Basel, Switzerland.

Lenskart Solutions Private Limited owns and operates an online shopping portal for men and women eyewear in India. It provides goggles, contact lenses, and sunglasses, as well as frames and sunglasses for kids. The company also owns and operates eyewear retail stores in India; and provides home eye check-up services in Mumbai, Bangalore, Chennai, Hyderabad, Kolkata, Pune, Delhi, Gurgaon, Noida, Faridabad, and Ghaziabad. Lenskart Solutions Private Limited was formerly known as Valyoo Technologies Private Limited and changed its name to Lenskart Solutions Private Limited in May 2015. The company was incorporated in 2008 and is based in New Delhi, India with retail stores in Delhi, Agartala, Nagpur, Ahmadabad, Mangalore, Kolhapur, Visakhapatnam, Hyderabad, Bengaluru, Sangli, Mumbai, Pune, Bhubaneshawar, Siliguri, Haridwar, Lucknow, Faridabad, Meerut, Erode, Ludhiana, Jamshedpur, Kolkata, Varanasi, Trivandrum, Kochi, Chennai, Tirupati, Raipur, Surat, Ranchi, Cuttack, Kannur, Dhanabad, Indore, and Madurai, India; and Goa.

HAYA Therapeutics is a developer of RNA-based therapeutics created to treat heart failure. The company's therapeutics utilizes biopharmaceutical therapy to target a heart specific regulator of fibrosis, the long noncoding RNA, enabling physicians to to block myocardial fibrosis and treat heart failure.

ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.

Bizongo is an innovative online B2B marketplace catering to the diverse packaging and material handling industries. It makes packaging sourcing, distribution, inventory management, and design hassle-free for enterprises. The company's automated supply chain platform ensures availability of packaging for business with lower inventory. It addresses challenges such as inventory stock out, excess inventory, and obsolescence that are common for enterprises. Bizongo was founded in 2015 by Aniket Deb, Ankit Tomar, and Sachin Agrawal and is headquartered in Mumbai, Maharashtra, India.

Secured Mail was established as a licensed postal operator in 2006 by managing director Mark Bigley. It has quickly grown to be the number three player in the wholesale Downstream Access (DSA) marketplace. With DSA, Secured Mail accesses Royal Mail’s Mail Centre network nationwide by collecting customers’ mail direct from the production facility before transporting it back to their own hubs. It is then sorted into mail centre order and delivered nationwide using their own fleet of vehicles. Royal Mail is contracted by Secured Mail to deliver this mail through the letterbox the day after receipt: ‘the Final Mile’. Today, Secured Mail’s client base includes Amazon, Domino’s Pizza and British Gas owner Centrica.

HAYA Therapeutics is a developer of RNA-based therapeutics created to treat heart failure. The company's therapeutics utilizes biopharmaceutical therapy to target a heart specific regulator of fibrosis, the long noncoding RNA, enabling physicians to to block myocardial fibrosis and treat heart failure.

Tessian’s mission is to secure the human layer. Using machine learning technology, Tessian automatically stops data breaches and security threats caused by human error - like data exfiltration, accidental data loss, business email compromise, and phishing attacks - with minimal disruption to employees' workflow. As a result, employees are empowered to do their best work, without security getting in their way. Founded in 2013, Tessian is backed by renowned investors like Sequoia, Accel, March Capital, and Balderton, and has offices in San Francisco and London.

Bizongo is an innovative online B2B marketplace catering to the diverse packaging and material handling industries. It makes packaging sourcing, distribution, inventory management, and design hassle-free for enterprises. The company's automated supply chain platform ensures availability of packaging for business with lower inventory. It addresses challenges such as inventory stock out, excess inventory, and obsolescence that are common for enterprises. Bizongo was founded in 2015 by Aniket Deb, Ankit Tomar, and Sachin Agrawal and is headquartered in Mumbai, Maharashtra, India.

iOnctura SA develops novel therapeutics to modulate and target immunosuppression in the tumor microenvironment. The company’s product pipeline includes selective Pi3K inhibitor, Anti-Lag 3 Ab, ATX inhibitor, Anti-CXCL12 Ab, and Anti-CD73 Ab. The company offers a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets novel drugs that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Its products offer clinical efficacy and expand the utility of checkpoint inhibitors. The company has partnerships with Merck and Cancer Research Technology. The company was founded in 2017 and is based in Geneva, Switzerland.

LEAP India Private Limited is engaged in selling and renting/pooling of pallets and foldable large containers (FLC). The company offers wooden pallets, plastic containers, wooden boxes, and metal wire mesh catering to various sectors. It also provides transportation facility to the customers for primary or secondary movement of products; inventory management; assets reconditioning and repairing services; and an online pallet management tool that allows customers to place orders, check delivery dates, view invoices, and generate reports. It serves to industries, including fast-moving consumer goods (FMCG), retail, beverage, and automobile. The company was founded in 2013 and is based in Mumbai, India.

Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines. REVOLUTION Medicines builds upon the vision of the company’s founder, Martin D. Burke, M.D., Ph.D., professor of chemistry, University of Illinois at Urbana-Champaign, and Early Career Scientist of the Howard Hughes Medical Institute, who invented a transformative method for synthesizing original compounds that are pharmaceutically optimized analogues of complex natural products. REVOLUTION Medicines has entered into an exclusive license agreement with the University of Illinois to practice and expand this technology. REVOLUTION Medicines’ approach is a rapid, standardized and powerful process for assembling simple “chemical building blocks” into refined natural product-like structures. These optimized compounds have significant potential as best-in-class drug candidates.

ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.

Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines. REVOLUTION Medicines builds upon the vision of the company’s founder, Martin D. Burke, M.D., Ph.D., professor of chemistry, University of Illinois at Urbana-Champaign, and Early Career Scientist of the Howard Hughes Medical Institute, who invented a transformative method for synthesizing original compounds that are pharmaceutically optimized analogues of complex natural products. REVOLUTION Medicines has entered into an exclusive license agreement with the University of Illinois to practice and expand this technology. REVOLUTION Medicines’ approach is a rapid, standardized and powerful process for assembling simple “chemical building blocks” into refined natural product-like structures. These optimized compounds have significant potential as best-in-class drug candidates.

Araris Biotech AG (Araris) is a biotechnology start-up company. Their aim is to deliver a breakthrough technology platform that enables the development of next-generation ADC-based safe and potent drugs for various diseases and ailments.They are committed to produce high quality ADCs that do not require any engineering (antibody and/or cell-line) for site-specific conjugation instead the antibodies can directly be taken 'off-the-shelf'. The site-specifically modified ADCs can thus be produced rapidly within a few days and quality control and analysis can be performed quickly with high confidence. Their ADC technology is backed by two patents.

Synendos Therapeutics AG, a biopharmaceutical company, develops therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain. It focuses on unmet medical needs in the areas of anxiety, mood, and stress-related disorders. Synendos Therapeutics AG was founded in 2019 and is based in Allschwil, Switzerland.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of avß1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.

Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of avß1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.

Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. It uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. The company was founded in 2012 and is based in Geneva, Switzerland. As of July 15, 2019, Amal Therapeutics SA operates as a subsidiary of Boehringer Ingelheim GmbH.

Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery. MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.

iOnctura SA develops novel therapeutics to modulate and target immunosuppression in the tumor microenvironment. The company’s product pipeline includes selective Pi3K inhibitor, Anti-Lag 3 Ab, ATX inhibitor, Anti-CXCL12 Ab, and Anti-CD73 Ab. The company offers a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets novel drugs that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Its products offer clinical efficacy and expand the utility of checkpoint inhibitors. The company has partnerships with Merck and Cancer Research Technology. The company was founded in 2017 and is based in Geneva, Switzerland.

Decibel Therapeutics is a developer of hearing disorder therapeutics intended to protect, repair and restore hearing. The company's therapeutics have provided insights into the link between hearing dysfunction and inner ear pathology and it has capabilities to encompass animal models, drug delivery to the inner ear, imaging, inner ear PK/PD modeling and measurement, bioinformatics, genetics and target identification, enabling patients to experience hearing loss therapies with different forms of hearing disorders for their recovery.

Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery. MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.

Airborne International is engaged in engineering, manufacturing, and supplying high-end composites structures for industries such as aerospace, defense, marine, high-end bicycles, and formula-one cars. It offers composites structures maintenance and repair services, including inspection and damage assessment, sealing and painting, and balancing. The company was founded in 1995 and is based in The Hague, the Netherlands.

ECheng (e成) is a B2B SaaS platform that provides HR matching and resume screening for enterprises. Using machine learning, data mining, and NLP (natural language processing), the company categorizes resumes that best fit the job requirements of the client company. The company was launched in 2013 by industry veterans from Baidu, IBM, and Microsoft, serving multinational conglomerates as well as small and medium-sized companies.

Goldfinch is a clinical-stage biotech company focused on discovering and developing precision therapies for patients with kidney disease. It is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease. Its Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets to treat progressive kidney disease. The company was founded in 2016 and is based in Cambridge, Massachusetts.

Mission Therapeutics is a drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Bizongo is an innovative online B2B marketplace catering to the diverse packaging and material handling industries. It makes packaging sourcing, distribution, inventory management, and design hassle-free for enterprises. The company's automated supply chain platform ensures availability of packaging for business with lower inventory. It addresses challenges such as inventory stock out, excess inventory, and obsolescence that are common for enterprises. Bizongo was founded in 2015 by Aniket Deb, Ankit Tomar, and Sachin Agrawal and is headquartered in Mumbai, Maharashtra, India.

Araris Biotech AG (Araris) is a biotechnology start-up company. Their aim is to deliver a breakthrough technology platform that enables the development of next-generation ADC-based safe and potent drugs for various diseases and ailments.They are committed to produce high quality ADCs that do not require any engineering (antibody and/or cell-line) for site-specific conjugation instead the antibodies can directly be taken 'off-the-shelf'. The site-specifically modified ADCs can thus be produced rapidly within a few days and quality control and analysis can be performed quickly with high confidence. Their ADC technology is backed by two patents.

FirstCry is an online portal for baby products and toys. They have over 20000+ items from 250+ top International and Indian brands like Mattel, Ben10, Pigeon, Funskool, Hotwheels, Nuby, Farlin, Medela, Pampers, Disney, Barbie, Gerber, Zapak, Mee Mee, and so on. The company provides best of the products and brands at the best prices with quality online shopping experience, fast and reliable delivery service, and a prompt customer care. FirstCry was founded in 2010 and is based in Pune, India.

ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.

Alentis Therapeutics AG develops and manufactures medications to treat advanced liver diseases. It develops medications for liver fibrosis, cirrhosis, and liver cancer. The company was founded in 2019 and is based in Basel, Switzerland.

AEVI International GmbH develops and provides an open ecosystem that combines applications, payment services, and a multi-vendor selection of payment devices.The company offers AEVI Digital Service Center, a vendor-agnostic and open platform that merchant solution providers can access as a one-stop-shop to pick and mix solutions for any stage of their digital strategies. It caters to retail, hospitality, postal, and financial service sectors. The company was incorporated in 2015 and is based in Paderborn, Germany. AEVI International GmbH operates as a subsidiary of Wincor Nixdorf International GmbH.

Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. It uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. The company was founded in 2012 and is based in Geneva, Switzerland. As of July 15, 2019, Amal Therapeutics SA operates as a subsidiary of Boehringer Ingelheim GmbH.

Rethink Robotics helps manufacturers meet the challenges of an agile economy with an integrated workforce, combining trainable, safe and cost-effective robots with skilled labor. Its Baxter robot, driven by Intera, an advanced software platform, gives world-class manufacturers and distributors in automotive, plastics, consumer goods, electronics and more, a workforce multiplier that optimizes labor. With Rethink Robotics, manufacturers increase flexibility, lower costs and can invest in skilled labor—all advantages in fueling continuous innovation and sustainable competitive advantage. Committed to accelerating robotics innovation in manufacturing and beyond, Rethink Robotics’ Baxter Research Robot gives academic and corporate research environments a humanoid robot platform with integrated sensors and an open software development kit for creating custom applications. Based in Boston, Massachusetts, the company is funded by Bezos Expeditions, Charles River Ventures, Highland Capital Partners, Sigma Partners, Draper Fisher Jurvetson, and Two Sigma Ventures.

Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.

Lenskart Solutions Private Limited owns and operates an online shopping portal for men and women eyewear in India. It provides goggles, contact lenses, and sunglasses, as well as frames and sunglasses for kids. The company also owns and operates eyewear retail stores in India; and provides home eye check-up services in Mumbai, Bangalore, Chennai, Hyderabad, Kolkata, Pune, Delhi, Gurgaon, Noida, Faridabad, and Ghaziabad. Lenskart Solutions Private Limited was formerly known as Valyoo Technologies Private Limited and changed its name to Lenskart Solutions Private Limited in May 2015. The company was incorporated in 2008 and is based in New Delhi, India with retail stores in Delhi, Agartala, Nagpur, Ahmadabad, Mangalore, Kolhapur, Visakhapatnam, Hyderabad, Bengaluru, Sangli, Mumbai, Pune, Bhubaneshawar, Siliguri, Haridwar, Lucknow, Faridabad, Meerut, Erode, Ludhiana, Jamshedpur, Kolkata, Varanasi, Trivandrum, Kochi, Chennai, Tirupati, Raipur, Surat, Ranchi, Cuttack, Kannur, Dhanabad, Indore, and Madurai, India; and Goa.